Pharma major Lupin announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC's Mepron oral suspension 750 mg/5 ml. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-sMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMPsMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately UsD 119 million in the US (IQVIA MAT September 2018).

Shares of the company gained Rs 6.3, or 0.74%, to settle at Rs 860.50. The total volume of shares traded was 80,498 at the BSE (Monday).